Recent Finacing
Recent Raise
Helmedix develops helminth-derived immune-modulating peptide therapeutics for autoimmune and inflammatory diseases, advancing candidates targeting rheumatoid arthritis, colitis, psoriasis, and multiple sclerosis using UTS ithree–licensed IP.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor